Compare GSK plc (GSK) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Thomson Reuters Corp — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while Thomson Reuters Corp trades at $98.23 (market cap $41.16B). The key difference: GSK plc is far larger — about 2.5× Thomson Reuters Corp's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TRI | |
|---|---|---|
Market Cap | $101.34B | $41.16B |
Sector | Health | Industrials |
52-Week High | $61.18 | $211.14 |
52-Week Low | $36.20 | $76.55 |
Enterprise Value | $121.95B | $43.12B |
Dividend Yield | 3.49% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Thomson Reuters (TRI) trades at $97.56, up 6.34% today, showing strong momentum amid positive technical signals. The company maintains robust fundamentals with $7.48B revenue, 19.93% net margin, and consistent earnings beats in recent quarters. Recent developments include a joint venture with KKR for the global print business and continued AI integration across legal and professional services. Technical indicators show bullish momentum with support at $91 and resistance at $93.
TRI presents a compelling investment case with strong analyst support (52% buy ratings) and a $129.96 consensus price target offering 33% upside. Key risks include execution challenges in AI adoption and potential margin pressure from restructuring. The company's solid cash flow generation and strategic partnerships position it well for sustained growth, though investors should monitor Q2 2026 earnings due August 5th for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
